

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM771510

| | |
|------------------------------|-------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | SECURITY INTEREST |
| SEQUENCE: | 3 |

CONVEYING PARTY DATA

| Name | Formerly | Execution Date | Entity Type |
|---|----------|----------------|-----------------------|
| Lantheus Medical Imaging, Inc. | | 12/02/2022 | Corporation: DELAWARE |
| Progenics Pharmaceuticals, Inc. | | 12/02/2022 | Corporation: DELAWARE |
| Molecular Insight Pharmaceuticals, Inc. | | 12/02/2022 | Corporation: DELAWARE |

RECEIVING PARTY DATA

| | |
|------------------------|---|
| Name: | CITIZENS BANK, N.A. |
| Street Address: | 28 State Street |
| City: | Boston |
| State/Country: | MASSACHUSETTS |
| Postal Code: | 02109 |
| Entity Type: | National Banking Association: UNITED STATES |

PROPERTY NUMBERS Total: 33

| Property Type | Number | Word Mark |
|----------------------|---------|--|
| Registration Number: | 6732087 | DEFINITY RT |
| Registration Number: | 6389760 | VIALMIX RFID |
| Registration Number: | 5987668 | LANTHEUS |
| Registration Number: | 5732396 | BRINGING PHYSIOLOGY AND FUNCTION TO LIGH |
| Registration Number: | 5144576 | CALIDOSE |
| Registration Number: | 4800046 | PINSYNC |
| Registration Number: | 4731737 | VUCIFIC |
| Registration Number: | 3919480 | |
| Registration Number: | 2628446 | VIALMIX |
| Registration Number: | 2897509 | QUADRAMET |
| Registration Number: | 3699730 | LANTHEUS MEDICAL IMAGING |
| Registration Number: | 2478324 | DEFINITY |
| Registration Number: | 2276361 | MIRALUMA |
| Registration Number: | 1812837 | TECHNELITE |

OP \$840.00 6732087

| Property Type | Number | Word Mark |
|----------------------|---------|-----------------------------|
| Registration Number: | 1812836 | TECHNELITE |
| Registration Number: | 1496535 | NEUROLITE |
| Registration Number: | 1484982 | CARDIOLITE |
| Registration Number: | 6120752 | PYLARIFY |
| Registration Number: | 5921779 | PROGENICS PHARMACEUTICALS |
| Registration Number: | 5637259 | PROGENICS PHARMACEUTICALS |
| Registration Number: | 5835950 | PROGENICS PHARMACEUTICALS |
| Registration Number: | 5944787 | AZEDRA SERVICE CONNECTION |
| Registration Number: | 5795290 | AZEDRA |
| Registration Number: | 5388568 | PYL RESEARCH ACCESS PROGRAM |
| Registration Number: | 6058956 | FIND FIGHT AND FOLLOW |
| Registration Number: | 5788132 | FIND FIGHT AND FOLLOW |
| Registration Number: | 5566264 | FIND FIGHT AND FOLLOW |
| Registration Number: | 5546399 | FIND FIGHT AND FOLLOW |
| Registration Number: | 5566265 | FIND FIGHT AND FOLLOW |
| Registration Number: | 4898869 | AZEDRA |
| Registration Number: | 3496687 | PROGENICS |
| Registration Number: | 3496688 | PROGENICS PHARMACEUTICALS |
| Registration Number: | 3261505 | MOLECULAR INSIGHT |

CORRESPONDENCE DATA

Fax Number: 7045032622

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 7045032600

Email: msheehan@kslaw.com

Correspondent Name: King & Spalding LLP

Address Line 1: 300 S. Tryon St., Ste 1700

Address Line 2: Attn: Moira Sheehan

Address Line 4: Charlotte, NORTH CAROLINA 28202

ATTORNEY DOCKET NUMBER: 18858.515238

NAME OF SUBMITTER: Moira Sheehan

SIGNATURE: /s/ Moira Sheehan

DATE SIGNED: 12/02/2022

Total Attachments: 8

source=Lantheus - Trademark Security Agreement (Executed)#page1.tif

source=Lantheus - Trademark Security Agreement (Executed)#page2.tif

source=Lantheus - Trademark Security Agreement (Executed)#page3.tif

source=Lantheus - Trademark Security Agreement (Executed)#page4.tif

source=Lantheus - Trademark Security Agreement (Executed)#page5.tif

source=Lantheus - Trademark Security Agreement (Executed)#page6.tif

source=Lantheus - Trademark Security Agreement (Executed)#page7.tif

source=Lantheus - Trademark Security Agreement (Executed)#page8.tif

TRADEMARK SECURITY AGREEMENT

This TRADEMARK SECURITY AGREEMENT, dated as of December 2, 2022 (“Trademark Security Agreement”), made by Lantheus Medical Imaging, Inc., a Delaware corporation, Progenics Pharmaceuticals, Inc., a Delaware corporation, Molecular Insight Pharmaceuticals, Inc., a Delaware corporation, (each, a “Grantor”), is in favor of CITIZENS BANK, N.A., as collateral agent (in such capacity, the “Collateral Agent”) for the Secured Parties.

WITNESSETH:

WHEREAS, each Grantor is party to that certain Guarantee and Collateral Agreement, dated as of December 2, 2022 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Guarantee and Collateral Agreement”), in favor of the Collateral Agent, pursuant to which each Grantor is required to execute and deliver this Trademark Security Agreement (capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Guarantee and Collateral Agreement);

WHEREAS, pursuant to the terms of the Guarantee and Collateral Agreement, each Grantor has created in favor of the Collateral Agent a security interest in the Trademark Collateral (as defined below);

NOW, THEREFORE, in consideration of the premises and to induce the Agents and the Lenders to enter into the Credit Agreement and to induce the Lenders to make their respective extensions of credit to the Borrower thereunder and to induce the Qualified Counterparties to enter into the Specified Swap Agreements and the Specified Cash Management Agreements and provide financial accommodation, each Grantor hereby agrees with the Collateral Agent, for the benefit of the Secured Parties, as follows:

Each Grantor hereby grants to the Collateral Agent, for the benefit of the Secured Parties, a security interest in all of the following property now owned or at any time hereafter acquired by such Grantor or in which such Grantor now has or at any time in the future may acquire any right, title or interest (collectively, the “Trademark Collateral”), as collateral security for the complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of all Secured Obligations:

(a) the registered and applied-for Trademarks of such Grantor listed on Schedule 1 attached hereto; and

(b) to the extent not covered by clause (a), all Proceeds of any of the foregoing;

provided, that (i) this Trademark Security Agreement shall not constitute a grant of a security interest in any property to the extent that and for as long as such grant of a security interest would be prohibited by the terms of the Guarantee and Collateral Agreement, including in any applications for trademarks or service marks filed in the PTO pursuant to 15 U.S.C. § 1051 Section 1(b) unless and until evidence of use of the mark in interstate commerce is submitted to and

accepted by the PTO pursuant to 15 U.S.C. § 1051 Section 1(c) or Section 1(d); and (ii) the security interest granted hereby (A) shall attach at all times to all proceeds of such property, (B) shall attach to such property immediately and automatically (without need for any further grant or act) at such time as the condition described in clause (i) ceases to exist and (C) to the extent severable, shall, in any event, attach to all rights in respect of such property that are not subject to the applicable condition described in clause (i).

The security interest granted pursuant to this Trademark Security Agreement is granted in conjunction with security interest granted to the Collateral Agent pursuant to the Guarantee and Collateral Agreement and each Grantor hereby acknowledges and affirms that the rights and remedies of the Collateral Agent with respect to the security interest in the Trademarks made and granted hereby are more fully set forth in the Guarantee and Collateral Agreement. In the event that any provision of this Trademark Security Agreement is deemed to conflict with the Guarantee and Collateral Agreement, the provisions of the Guarantee and Collateral Agreement shall govern.

The term of this Trademark Security Agreement shall be co-terminus with the Guarantee and Collateral Agreement. Upon termination of this Trademark Security Agreement, all liens on and security interests in the Trademark Collateral shall be deemed automatically released upon the payment and performance of the Secured Obligations (other than any outstanding indemnification obligations). Upon the termination of this Trademark Security Agreement, the Collateral Agent shall execute all documents, make all filings, take all other actions reasonably requested by the Grantors to evidence and record the release of the lien on and security interests in the Trademark Collateral granted herein, all at the Grantors' sole cost and expense.

Each Grantor hereby authorizes and requests that the Commissioner of Patents and Trademarks record this Trademark Security Agreement.


THIS TRADEMARK SECURITY AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES UNDER THIS TRADEMARK SECURITY AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK WITHOUT REGARD TO CONFLICT OF LAW PRINCIPLES THAT WOULD RESULT IN THE APPLICATION OF ANY LAW OTHER THAN THE LAW OF THE STATE OF NEW YORK.

This Trademark Security Agreement may be executed by one or more of the parties to this Trademark Security Agreement on any number of separate counterparts, and all of said counterparts taken together shall be deemed to constitute one and the same instrument. Delivery of an executed signature page of this Trademark Security Agreement by facsimile transmission or electronic transmission (in “.pdf” or similar format) shall be effective as delivery of a manually executed counterpart hereof. A set of the copies of this Trademark Security Agreement signed by all the parties shall be lodged with the Borrower, the Administrative Agent and the Collateral Agent.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

IN WITNESS WHEREOF, each Grantor has caused this TRADEMARK SECURITY AGREEMENT to be executed and delivered by its duly authorized officer as of the date first above written.


LANTHEUS MEDICAL IMAGING, INC.

By: 
Name: Robert J. Marshall, Jr.
Title: Chief Financial Officer and Treasurer

MOLECULAR INSIGHT PHARMACEUTICALS, INC.

By: 
Name: Robert J. Marshall, Jr.
Title: Treasurer

PROGENICS PHARMACEUTICALS, INC.

By: 
Name: Robert J. Marshall, Jr.
Title: Chief Financial Officer and Treasurer

Accepted and Agreed:

CITIZENS BANK, N.A.,
as Collateral Agent

By: _____
Name:
Title:

[SIGNATURE PAGE TO TRADEMARK SECURITY AGREEMENT]

TRADEMARK
REEL: 007907 FRAME: 0303

IN WITNESS WHEREOF, each Grantor has caused this TRADEMARK SECURITY AGREEMENT to be executed and delivered by its duly authorized officer as of the date first above written.

LANTHEUS MEDICAL IMAGING, INC.

By: _____
Name: Robert J. Marshall, Jr.
Title: Chief Financial Officer and Treasurer

MOLECULAR INSIGHT PHARMACEUTICALS,
INC.


By: _____
Name: Robert J. Marshall, Jr.
Title: Treasurer

PROGENICS PHARMACEUTICALS, INC.

By: _____
Name: Robert J. Marshall, Jr.
Title: Chief Financial Officer and Treasurer

Accepted and Agreed:

CITIZENS BANK, N.A.,
as Collateral Agent

By: 
Name: John F. Kendrick
Title: Vice President


[SIGNATURE PAGE TO TRADEMARK SECURITY AGREEMENT]

TRADEMARK
REEL: 007907 FRAME: 0304

Schedule 1

TRADEMARKS

Trademarks

| Trademark | App. No/App. Date | Reg. No./Reg. Date | Owner |
|--|------------------------|-----------------------|--------------------------------------|
| DEFINITY RT | 88195016 11/15/2018 | 6732087 05/24/2022 | LANTHEUS MEDICAL IMAGING, INC. |
| VIALMIX RFID | 88195047 11/15/2018 | 6389760 06/15/2021 | LANTHEUS MEDICAL IMAGING, INC. |
| LANTHEUS | 88248414 01/03/2019 | 5987668 02/18/2020 | LANTHEUS MEDICAL IMAGING, INC. |
| BRINGING PHYSIOLOGY AND FUNCTION TO LIGHT ON THE PATHWAY OF PATIENT CARE | 88084584 08/20/2018 | 5732396 08/23/2019 | LANTHEUS MEDICAL IMAGING, INC. |
| CALIDOSE | 86872317 01/12/2016 | 5144576 02/21/2017 | LANTHEUS MEDICAL IMAGING, INC. |
| PINSYNC | 85727915 09/13/2012 | 4800046 08/25/2015 | LANTHEUS MEDICAL IMAGING, INC. |
| VUCIFIC | 85301044 04/21/2011 | 4731737 05/05/2015 | LANTHEUS MEDICAL IMAGING, INC. |
|  | 85072700 06/28/2010 | 3919480 02/15/2011 | LANTHEUS MEDICAL IMAGING, INC. |
| VIALMIX | 78100860 01/04/2002 | 2628446 10/01/2002 | LANTHEUS MEDICAL IMAGING, INC. |

| | | | |
|------------------------------|------------------------|-----------------------|---------------------------------------|
| QUADRAMET | 78374967 02/26/2004 | 2897509 10/26/2004 | LANTHEUS MEDICAL IMAGING, INC. |
| LANTHEUS MEDICAL IMAGING | 77394021 02/11/2008 | 3699730 10/20/2009 | LANTHEUS MEDICAL IMAGING, INC. |
| DEFINITY | 75479438 05/05/1998 | 2478324 08/14/2001 | LANTHEUS MEDICAL IMAGING, INC. |
| MIRALUMA | 75237528 02/06/1997 | 2276361 09/07/1999 | LANTHEUS MEDICAL IMAGING, INC. |
| TECHNELITE | 74254668 03/12/1992 | 1812837 12/21/1993 | LANTHEUS MEDICAL IMAGING, INC. |
| TECHNELITE | 74254537 03/12/1992 | 1812836 12/21/1993 | LANTHEUS MEDICAL IMAGING, INC. |
| NEUROLITE | 73700614 12/14/1987 | 1496535 07/19/1988 | LANTHEUS MEDICAL IMAGING, INC. |
| CARDIOLITE | 73662052 05/21/1987 | 1484982 04/19/1988 | LANTHEUS MEDICAL IMAGING, INC. |
| PYLARIFY | 88978293 10/08/2019 | 6120752 08/04/2020 | PROGENICS PHARMACEUTICALS, INC. |
| PROGENICS PHARMACEUTICALS | 87894837 04/27/2018 | 5921779 11/26/2019 | PROGENICS PHARMACEUTICALS, INC. |
| PROGENICS PHARMACEUTICALS | 87897248 04/27/2018 | 5637259 12/25/2018 | PROGENICS PHARMACEUTICALS, INC. |

| | | | |
|--------------------------------|------------------------|-----------------------|---------------------------------------|
| PROGENICS PHARMACEUTICALS | 87981227 04/27/2018 | 5835950 08/13/2019 | PROGENICS PHARMACEUTICALS, INC. |
| AZEDRA SERVICE CONNECTION | 87730345 12/21/2017 | 5944787 12/24/2019 | PROGENICS PHARMACEUTICALS, INC. |
| AZEDRA | 87722774 12/15/2017 | 5795290 07/02/2019 | PROGENICS PHARMACEUTICALS, INC. |
| PYL RESEARCH ACCESS PROGRAM | 87976381 10/25/2016 | 5388568 01/23/2018 | PROGENICS PHARMACEUTICALS, INC. |
| FIND FIGHT AND FOLLOW | 87034938 05/12/2016 | 6058956 05/19/2020 | PROGENICS PHARMACEUTICALS, INC. |
| FIND FIGHT AND FOLLOW | 87034964 05/12/2016 | 5788132 06/25/2019 | PROGENICS PHARMACEUTICALS, INC. |
| FIND FIGHT AND FOLLOW | 87035388 05/12/2016 | 5566264 09/18/2018 | PROGENICS PHARMACEUTICALS, INC. |
| FIND FIGHT AND FOLLOW | 87035396 05/12/2016 | 5546399 08/21/2018 | PROGENICS PHARMACEUTICALS, INC. |
| FIND FIGHT AND FOLLOW | 87035406 05/12/2016 | 5566265 09/18/2018 | PROGENICS PHARMACEUTICALS, INC. |
| AZEDRA | 85731453 09/18/2012 | 4898869 02/09/2016 | PROGENICS PHARMACEUTICALS, INC. |
| PROGENICS | 77183765 05/17/2007 | 3496687 09/02/2008 | PROGENICS PHARMACEUTICALS, INC. |

| | | | |
|------------------------------|------------------------|-----------------------|--|
| PROGENICS PHARMACEUTICALS | 77183789 05/17/2007 | 3496688 09/02/2008 | PROGENICS PHARMACEUTICALS, INC. |
| MOLECULAR INSIGHT | 76582783 03/22/2004 | 3261505 07/10/2007 | MOLECULAR INSIGHT PHARMACEUTICALS, INC. |